The First National Blood Borne Viruses and Sexually Transmissible Infections Research Strategy 2021-2025
The First National Blood Borne Viruses (BBV) and Sexually Transmissible Infections (STI) Research Strategy (the Strategy) will ensure that future funded research activities best align with the priorities of the BBV and STI research agenda and support measurable progress towards the goals and targets of the five National BBV and STI Strategies.
The five National BBV and STI Strategies set the direction for Australia’s continuing response, and represent the commitment of Australian governments, researchers and health and community organisations to address the impact of BBVs and STIs on the Australian community.
The Strategy aims to support nationally relevant research and innovation, and capacity building in reducing the incidence and impact of BBVs and STIs in Australia. The Strategy builds on the considerable work already being progressed collaboratively by governments, community-based organisations, researchers, health professionals and communities to improve health outcomes for people at risk of, and living with, BBV and STIs.
- The First National Blood Borne Viruses and Sexually Transmissible Infections Research Strategy 2021-2025 (PDF 924 KB)
- The First National Blood Borne Viruses and Sexually Transmissible Infections Research Strategy 2021-2025 (Word 905 KB)
Review of Commonwealth funding of services to support the diagnosis and screening of Blood Borne Viruses
The Commonwealth commissioned an independent review of funding of services to support the diagnosis and screening of blood borne viruses. The review assessed Australian Government funding of the services delivered by the National Serology Reference Laboratory within current regulatory, laboratory accreditation and public health contexts. The final report of the review is available to download:
- Review of Commonwealth Funding of Services to Support the Diagnosis and Screening of Blood Borne Viruses - Final Report (PDF 1117 KB)
- Review of Commonwealth Funding of Services to Support the Diagnosis and Screening of Blood Borne Viruses - Final Report (Word 1953 KB)
National Guidelines for Managing HIV Transmission Risk Behaviours (2018)
The National Guidelines for Managing HIV Transmission Risk Behaviours 2018 have been developed in consultation with the Blood Borne Viruses and Sexually Transmissible Infections Standing Committee (BBVSS) and the Communicable Disease Network Australia (CDNA), and endorsed by their parent committee the Australian Health Protection Principal Committee (AHPPC).
On 29 November 2018, the five National Blood Borne Viruses (BBV) and Sexually Transmissible Infections (STI) Strategies 2018-2022 were publicly released. You can access the strategies by following the links below links.
Australia has continued to make significant progress in addressing blood-borne viruses (BBV) and sexually transmissible infections (STI) over the period of the previous national strategies.
The National BBV and STI Strategies for 2018-2022 set the direction for Australia’s continuing response. Together they outline a framework for a high-quality and coordinated national response.
The national strategies are endorsed by all Australian Health Ministers. The ambitious targets and goals outlined in the national strategies will continue to guide Australia’s efforts to significantly reduce the transmission of BBV and STI, and improve rates of diagnosis and treatment. Importantly, they will also focus actions on improving the quality of life for people with BBV and/or STI and addressing the stigma people still experience.
The national strategies capitalise on the significant headway that has been made in recent years in our response to BBV and STI. This includes the listing of Pre-Exposure Prophylaxis (PrEP) for HIV prevention, additional HIV treatment medicines, and ensuring the broadest possible access to new direct acting antiviral treatments for hepatitis C on the Pharmaceutical Benefits Scheme. Maintaining our momentum is essential – we now have the potential to considerably advance our response across some critical areas.
The success of these strategies relies on continuing to build a strong evidence base to better inform our responses, evaluating our approaches to identify what is most effective, and further strengthening our workforce, partnerships and connections to priority populations.
These national strategies recognise the considerable work already being progressed collaboratively by governments, community-based organisations, researchers, health professionals and communities.
Despite our efforts, the strategies identify trends of concern and gaps in our response. The development of these strategies has highlighted the significant collegiality and commitment of stakeholders to strengthening our BBV and STI response. With this foundation, Australia can continue to strive to achieve great things, building on our reputation as a world leading model of best-practice.
The Hon Greg Hunt MP
Minister for Health
Eighth National HIV Strategy
Fifth National Aboriginal and Torres Strait Islander BBV and STI Strategy
- Fifth National Aboriginal and Torres Strait Islander BBV and STI Strategy - PDF 8097 KB
- Fifth National Aboriginal and Torres Strait Islander BBV and STI Strategy - Word 1278 KB
Fifth National Hepatitis C Strategy
Fourth National STI Strategy
Third National Hepatitis B Strategy
The five National BBV and STI Strategies represent the commitment of Australian Governments, researchers and health and community organisations to address the impact of BBV and STI on the Australian community. Together they form a framework and agreed direction for a high quality and coordinated national response to BBV and STI for 2018–2022.
Action Plans will be developed to support the implementation of the National BBV and STI Strategies and provide the detail of more specific actions for governments and partners. The Action Plans will be developed in consultation with stakeholders.
Communique from the Collaborative Human T-Lymphotropic Virus Type-1 Forum – August 2018
Human T-Lymphotropic Type-1 (HTLV-1) is a virus that occurs in diverse communities around the world and has been present among Aboriginal people in Central Australia for thousands of years. The type of the virus found in Central Australia, type C, is unique to our part of the world. Preliminary data suggests high rates of this virus in some communities in Central Australia.
Current evidence shows that infection with this virus is not likely to cause disease in a majority of people. International research shows that, in a small proportion of people after many decades, HTLV-1 causes a rare form of leukaemia and/or a spinal cord disease. Studies have suggested associations with other diseases but it is not yet known whether it causes those diseases or not. The true burden of disease of HTLV-1 in our communities needs further research.
On Friday 25 May 2018, Ministers Hunt and Wyatt announced that funding of $8 million from 2018-19 to 2019-20 will be provided to support an enhanced response to communicable diseases in Indigenous communities, including HTLV-1. Funding will be provided to determine appropriate evidence-based responses to HTLV-1 and other communicable diseases in remote Indigenous communities.
On 28 and 29 August 2018, a collaborative forum was held and included representatives from Aboriginal leaders, community and patient representatives, researchers, representatives from Aboriginal community-controlled health services, clinicians, public health officials, and representatives from Commonwealth and state and territory health departments.
The forum is the first step in determining priority activities to improve understanding of the virus, its epidemiology and appropriate public health responses.
The forum reaffirmed the importance of Aboriginal leadership in this process and agreed on the following statement:
The summary outcomes of the Collaborative HTLV-1 Forum are available to download. This is a jointly owned document which reflects the discussions of participants at the forum.
The department, working through the Australian Health Ministers’ Advisory Council and its sub-committees, facilitates national policy formulation and coordination for blood borne viruses (BBVs) and sexually transmissible infections (STIs). In particular:
The Blood Borne Viruses and Sexually Transmissible Infections Standing Committee (BBVSS)
The BBVSS is a key advisory body reporting to the Australian Health Ministers’ Advisory Council (AHMAC) through the Australian Health Protection Principal Committee (AHPPC) on strategic policy, programs, social issues and activities related to HIV, viral hepatitis and STIs. The BBVSS forms part of a coordinated response across Australian Government, state and territory government, key organisations, peak bodies and national research centres for hepatitis B, hepatitis C, HIV, STIs and Aboriginal and Torres Strait Islander blood borne viruses and sexually transmissible infections.
The Australian Government further seeks advice through:
Ministerial Advisory Committee on Blood Borne Viruses and Sexually Transmissible Infections (MACBBVS)
The MACBBVS is the Australian Government’s key advisory body on the national response and management of blood borne viruses and sexually transmissible infections. It is responsible for providing independent and expert advice to the Minister for Health on BBVs and STIs. MACBBVS works as an advisory structure and its key role is to provide specialist advice to inform the Australian Government’s response to BBVs and STIs, identify emerging issues and ways these may be addressed.
Any BBV and STI enquiries should be directed to BBVSTITSH@health.gov.au.
National BBV and STI Surveillance and Monitoring Plan 2018-2022
The National BBV and STI Surveillance and Monitoring Plan 2018-2022 supports the National BBV and STI Strategies 2018-22. The Plan monitors progress towards achieving the targets of the National Strategies.
- National BBV and STI Surveillance and Monitoring Plan 2018-2022 (PDF 2946 KB)
- National BBV and STI Surveillance and Monitoring Plan 2018-2022 (Word 322 KB)